|January 8, 2013|
|10:00 EDT||PH, TKC, MKSI, KKR, CELG, VTR, MGM, SPN, MFC, JOY, DOV, HEK, RDC, LUV, LSTR, FTI||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Outperform from Sector Perform at RBC Capital... Celgene (CELG) upgraded to Overweight from Neutral at Piper Jaffray... Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Buy from Neutral at Sterne Agee... Joy Global (JOY) upgraded to Overweight from Neutral at Piper Jaffray... KKR & Co. (KKR) upgraded to Buy from Neutral at Goldman... Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo... MKS Instruments (MKSI) upgraded to Buy from Neutral at BofA/Merrill... Manulife Financial (MFC) upgraded to Buy from Neutral at BofA/Merrill... Southwest (LUV) upgraded to Buy from Hold at Deutsche Bank... Superior Energy (SPN) upgraded to Outperform from Sector Perform at RBC Capital... Turkcell (TKC) upgraded to Overweight from Neutral at HSBC... Rowan Companies (RDC) upgraded to Neutral from Underweight at JPMorgan... MGM Resorts (MGM) upgraded to Outperform from Neutral at Credit Suisse... Parker-Hannifin (PH)upgraded to Overweight from Neutral at JPMorgan... Ventas (VTR) upgraded to Buy from Hold at Jefferies... Heckmann (HEK) upgraded to Neutral from Sell at Ladenburg.
News For DOV;CELG;FTI;JOY;KKR;LSTR;MFC;MKSI;LUV;SPN;TKC;RDC;MGM;PH;HEK;VTR From The Last 14 Days
|September 25, 2015|
|16:17 EDT||CELG||On The Fly: Top stock stories for Friday|
Stocks opened with sharp gains the day after Fed Chair Janet Yellen gave some clarity to the market by suggesting the Fed will most likely raise interest rates by the end of the year. During afternoon trading, the news flow slowed and the volume lightened on the buy side, leaving the sellers with the upper hand. The Nasdaq was the first index to move into negative territory, led by broad weakness in biotech stocks, while the Dow was helped to stay in the green by a big post-earnings move higher in Nike (NKE). The averages limped into the close, leaving the market with an interesting set-up to begin next week. Outside of stock news, it was certainly a headline packed day, as Speaker of the House John Boehner announced that he will resign at the end of October, Chinese President Xi Jinping continued his U.S. visit and Pope Francis addressed the United Nations while spending a second day in New York City. ECONOMIC EVENTS: In the U.S., the third estimate of second quarter GDP showed the economy grew 3.9% quarter-over-quarter, versus expectations for the GDP growth estimate to stay at 3.7%. Personal consumption in Q2 is now believed to have grown 3.6%, up from the prior estimate of 3.1%. The final University of Michigan consumer sentiment reading for September came in at 87.2, which was down from August's 91.9 but above the expected 86.2 reading... Federal Reserve Chair Janet Yellen said during a speech at UMass Amherst last night that the central bank remains inclined to hike rates this year. Yellen's remarks were incrementally hawkish, but welcomed by the market, since they helped clarify the message the Fed delivered a week ago. Of note, the Fed chair paused multiple times toward the end of her speech and received medical attention afterward, but returned to her regular schedule later in the evening, with the bank explaining that Yellen was dehydrated after a long day but was otherwise fine. COMPANY NEWS: Nike jumped $10.23, or 8.9%, to $125.02 after Thursday night's report of better than expected earnings and futures orders prompted numerous price target hikes at Street research firms. Additionally, Sterne Agee upgraded Nike to Buy from Neutral, saying it thinks the company is benefiting from its "global grass roots engagement with its customers," which enables it to meet its customers' needs and determine to what extent it can raise prices. The firm, which thinks that the company is continuing to gain share, has a $150 price target on the athletic gear giant... Biotech stocks, which were already having a bad week, ended the week on a down note, as the iShares NASDAQ Biotechnology Index (IBB) fell 4.9%, giving it a weekly decline of about 13%. Among the biggest large-cap losers in the space were Vertex (VRTX), which fell 7%, Regeneron (REGN), which dropped 6% and Celgene (CELG), which slid 4.8%. MAJOR MOVERS: Among the notable gainers was Jabil Circuit (JBL), which advanced $2.38, or 12.2%, to $21.88 after it reported higher than expected earnings and gave guidance for its November quarter that was significantly above expectations. Also higher was Cirrus Logic (CRUS), which gained $3.90, or 14.4%, to $31.03 after tear downs of Apple's (AAPL) iPhone 6S and 6S Plus led analysts to conclude that the chipmaker appears poised to obtain more revenue from the new devices than from the previous generation of the market-leading smartphone. Among the noteworthy losers was Finish Line (FINL), which fell $4.86, or 19.6%, to $19.91 after reporting second quarter revenue that missed expectations and saying it expects adjusted earnings this fiscal year to increase in a low single to mid single digits percentage from last year. Also lower following its earnings report was smartphone and software maker BlackBerry (BBRY), which slid 7.68% to $6.49 after the company posted a second quarter loss that was steeper than analysts expected. BlackBerry also confirmed press reports that it plans to launch a new phone that uses Google's (GOOG) Android operating system instead of its own proprietary BB10 OS. Shares of Aratana Therapeutics (PETX), which dropped $6.81, or 38.97%, to $10.68 after the company said that, based on "mixed clinical and scientific results," it does not believe that canine lymphoma products AT-004 and AT-005 in their current, first-generation forms will capture the desired lymphoma market opportunity. INDEXES: The Dow rose 113.35, or 0.7%, to 16,314.67, the Nasdaq fell 47.98, or 1.01%, to 4,686.50, and the S&P 500 added/slipped 0.90, or 0.05%, to 1,931.34.
|10:00 EDT||JOY||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: AGCO (AGCO) initiated with an Equal Weight at Barclays... ARM Holdings (ARMH) initiated with a Buy at Stifel... Actuant (ATU) initiated with an Equal Weight at Barclays... Allison Transmission (ALSN) initiated with an Overweight at Barclays... Atara Biotherapeutics (ATRA) initiated with an Outperform at JMP Securities... Big Lots (BIG) initiated with a Buy at Citi... CNH Industrial (CNHI) initiated with an Underweight at Barclays... CareDx (CDNA) initiated with a Buy at Craig-Hallum... Caterpillar (CAT) initiated with an Equal Weight at Barclays... Cummins (CMI) initiated with an Underweight at Barclays... Deere (DE) initiated with an Underweight at Barclays... Genesis Energy (GEL) initiated with a Buy at Wunderlich... Joy Global (JOY) initiated with an Equal Weight at Barclays... Lincoln Electric (LECO) initiated with a Neutral at Baird... Manitowoc (MTW) initiated with an Equal Weight at Barclays... Navistar (NAV) initiated with an Underweight at Barclays... Nevro (NVRO) initiated with an Outperform at BMO Capital... PACCAR (PCAR) initiated with an Underweight at Barclays... PBF Energy (PBF) initiated with a Neutral at Goldman... PayPal (PYPL) initiated with a Buy at Canaccord... Quanex (NX) initiated with a Buy at Sidoti... Team Health (TMH) initiated with a Buy at Jefferies... Terex (TEX) initiated with an Equal Weight at Barclays... United Rentals (URI) initiated with an Overweight at Barclays... WABCO (WBC) initiated with an Equal Weight at Barclays.
|07:22 EDT||CELG||European Society for Medical Oncology to hold a conference|
Subscribe for More Information
|05:51 EDT||JOY||Barclays starts U.S. Machinery space with Negative view|
Barclays analyst Robert Wertheimer rolled out coverage of the U.S. Machinery space with a Negative view. Of the fifteen companies he initiated in the sector, only two are Overweight rated. Wertheimer started five names at Underweight, his firm's equivalent of a sell. Consensus estimates are too high across the board with revenue for this cycle already peaking for most of machinery, the analyst told investors last night in a research note. He sees a sharper downturn for North American trucks than the consensus expects, with another peak level eight years away. And the tractor supercycle is only two years in a downturn, while the prior two supercycles saw seven consecutive down years in machinery sales, Wertheimer adds. Allison Transmission (ALSN) and United Rentals (URI) are the analyst's Overweight-rated stocks in the sector. Deere (DE), CNH Industrial (CNHI), Cummins (CMI), PACCAR (PCAR) and Navistar (NAV) are his Underweight rated names. Wertheimer also started with Equal Weight ratings shares of Actuant (ATU), AGCO (AGCO), Caterpillar (CAT), Joy Global (JOY), Lincoln Electric (LECO), Manitowoc (MTW), Terex (TEX) and WABCO (WBC).
|05:21 EDT||CELG||Celgene's VIDAZA receives positive CHMP opinion|
Subscribe for More Information
|September 24, 2015|
|16:26 EDT||JOY||Joy Global initiated with an Equal Weight at Barclays|
Subscribe for More Information
|16:14 EDT||JOY||On The Fly: Top stock stories for Thursday|
Stock futures were weak in early pre-market trading and the negative bias was cemented when Dow member Caterpillar (CAT) announced restructuring actions, including plans to cut as many as 10,000 jobs, and slashed its revenue guidance for this fiscal year and next. For most of the day the sellers remained in control, pushing the market down more than 1.5% at one point. In the afternoon, though, the buyers came in and began to pick up perceived bargains, paring the market's losses. The averages closed well off their worst levels, but still in the red, ahead of a much-anticipated speech this evening from Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., there were 267,000 initial jobless claims last week, versus expectations for 272,000 first-time claims. Durable goods orders for August declined 2.0%, versus expectations for a drop of 2.3%. When transportation items were removed, the core reading was breakeven, versus expectations for a rise of 0.1%. The Chicago Fed National Activity Index had a reading of -0.41, versus expectations of +0.24. New home sales jumped 5.7% in August to a 552,000 rate, versus expectations for a rise of 1.6% to a 515,000 rate. In Asia, Japan's stock market reopened for the first time since Friday and the Nikkei suffered a nearly 3% decline as it caught up to other global markets. The slide came despite Japanese Prime Minister Shinzo Abe unveiling new economic targets, including a goal for a 20% increase in the target size of the Japanese economy to 600T yen, though he gave no timeframe for achieving this aspiration. Elsewhere, Norway and Taiwan both cut interest rates this morning. The Norges Bank lowered rates by 25 basis points to 0.75%, while Taiwan cut its benchmark by 12.5 basis points to 1.75% in the nation's first lowering of rates since 2009. COMPANY NEWS: Shares of Caterpillar fell $4.40, or 6.27%, to $65.80 after the heavy machinery maker announced plans for job cuts and lowered its revenue guidance for this year and next. Caterpillar said that it would lay off 4,000-5,000 of its employees between now and the end of 2016 and could lay off up to 10,000 employees by 2018. Caterpillar cut its fiscal year 2015 revenue forecast by $1B and said its sees its fiscal year 2016 revenue to be 5% below this year, adding that it expects revenue declines in all three large segments next year. Before the news was announced, research firm Axiom initiated coverage of Caterpillar with a Sell rating and $28 price target, projecting that the company's calendar 2016 earnings will fall well below the Street consensus view. Other mining and agriculture equipment makers were also weaker following the Dow member's announcement, with Joy Global (JOY) falling 1% and Deere (DE) dropping 2.5%. MAJOR MOVERS: Among the notable gainers was STERIS (STE), which advanced $5.05, or 8.02%, to $68.00 after the Federal Trade Commission was denied an injunction to stop the company's proposed merger with Synergy. Also higher was Diamond Foods (DMND), which gained $2.98, or 9.72%, to $33.65 after dealReporter said the company has held talks with strategic suitors as it explores a potential sale. Among the noteworthy losers was Sientra (SIEN), which crashed $10.88, or 52.87%, to $9.70 after a U.K. regulator suspended the CE certificate for all medical devices made by Silimed, the company's contracted manufacturer. Also lower was Caesars (CZR), which fell 6.6% to $7.51 after Bloomberg reported that the company has reached an impasse in talks with certain junior bondholders and creditors involved in the ongoing restructuring of its operating unit. INDEXES: The Dow fell 78.57, or 0.48%, to 16,201.32, the Nasdaq dropped 18.27, or 0.38%, to 4,734.48, and the S&P 500 lost 6.52, or 0.34%, to 1,932.24.
|13:19 EDT||JOY||On The Fly: Top stock stories at midday|
Stocks on Wall Street were sharply lower at midday, with each of the major indexes down more than 1%. Continued weakness in Asia and a lack of clarity regarding the Fed's rate decision last week has kept buyers on the sidelines while the sellers have had their way. Lowered guidance from Dow component Caterpillar (CAT) has weighed on the market in addition to some economic data points that were below expectations. ECONOMIC EVENTS: In the U.S., initial jobless claims were 267,000, versus expectations for 272,000 first-time claims. Durable goods orders for August declined 2.0%, versus expectations for a drop of 2.3%. When transportation items were removed, the core reading was breakeven, versus expectations for a rise of 0.1%. The Chicago Fed National Activity Index had a reading of -0.41, versus expectations of +0.24. New home sales jumped 5.7% in August to a 552,000 rate, versus expectations for a rise of 1.6% to a 515,000 rate. In Asia, Japan's stock market reopened for the first time since Friday and the Nikkei suffered a nearly 3% decline as it caught up to other global market trends in the week-to-date. The slide came despite Japanese Prime Minister Shinzo Abe unveiling new economic targets, including a goal for a 20% increase in the target size of the Japanese economy to 600T yen, though he gave no timeframe for achieving this aspiration. Elsewhere, Norway and Taiwan both cut interest rates this morning. The Norges Bank lowered rates by 25 basis points to 0.75%, while Taiwan cut its benchmark by 12.5 basis points to 1.75% in the nation's first lowering of rates since 2009. COMPANY NEWS: A slide in shares of Caterpillar weighed on the Dow Jones Industrial Average after the heavy machinery maker announced plans for job cuts and lowered its revenue guidance for this year and next. Caterpillar said that it would lay off 4,000-5,000 of its employees between now and the end of 2016 and could lay off up to 10,000 employees by 2018. Before the news was announced, research firm Axiom initiated coverage of Caterpillar with a Sell rating and $28 price target, which its shares were 5.7% closer to at midday following their swoon. Other mining and agriculture equipment makers, including Joy Global and Deere (DE), were also weaker following the Dow member's announcement. MAJOR MOVERS: Among the notable gainers was Arrowhead Research (ARWR), which rose 18% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection. Also higher was Hudson City Bancorp (HCBK), the parent company of Hudson City Savings Bank, which gained 3% after the bank, the Justice Department and CFPB reached a settlement to resolve allegations that the bank engaged in a pattern or practice of "redlining" predominantly Black and Hispanic neighborhoods in its residential mortgage lending practices. Notably, settling the allegations may pave the way for the bank to close out a proposed merger with M&T Bank (MTB). Among the noteworthy losers was Sientra (SIEN), which dropped 42% after disclosing that the U.K.'s Medicines and Healthcare products Regulatory Agency announced the suspension of the CE certificate for all medical devices made by Silimed, the company's contract manufacturer. Also lower were shares of Twitter (TWTR), which slid 4% after Citi cut its estimates below consensus and lowered its price target on the microblog service operator to $30. INDEXES: Near midday, the Dow was down 186.90, or 1.15%, to 16,092.99, the Nasdaq was down 56.64, or 1.19%, to 4,696.10, and the S&P 500 was down 20.18, or 1.04%, to 1,918.58.
|10:39 EDT||JOY||Axiom says sell Caterpillar before company cuts guidance, jobs|
The shares of heavy machinery maker Caterpillar (CAT) are tumbling after the company reduced its revenue guidance and announced that it would lay off 4,000-5,000 of its employees between now and the end of 2016. The company said it could lay off up to 10,000 employees by 2018. Before the news was announced, research firm Axiom initiated coverage of Caterpillar with a Sell rating, saying that the company will probably face "operating income headwinds." WHAT'S NEW: Caterpillar reduced its fiscal 2015 revenue guidance to $48B from $49B. Analysts' consensus estimate was $48.8B. Additionally, the company expects its revenue to drop 5% in fiscal 2016 versus fiscal 2015. Caterpillar expects to reduce its annual total costs by $1.5B, the heavy machinery maker said, noting that it anticipates that it will pay about $2B in pre-tax charges related to the layoffs. ANALYST CALL: Axiom analyst Gordon Johnson II initiated Caterpillar with a Sell rating, saying that the company appears to carry "Russian roulette risk." The company's Resources and Energy and Transportation units generate the highest margins for Caterpillar but are currently struggling, Johnson said. Consequently, the company will probably "face operating income headwinds" as its revenue mix deteriorates, the analyst stated. In 2016, Caterpillar's earnings per share is likely to drop to $2.79, Johnson warned, versus analysts' consensus estimate of $4.53 prior to today's announcement. Moreover, after analyzing the SEC filings of Caterpillar's subsidiary, CAT Financial, Johnson believes that "the company is using debt to fund sales (where revenue is recognized) between itself and wholly-owned foreign (subsidiaries)." Citing a May 2013 letter between Caterpillar and the SEC, Johnson says that the agency has noticed this phenomenon, limiting Caterpillar's ability to employ similar methods during the current downturn. He set a $28 price target on the stock. OTHERS TO WATCH: Other heavy machinery makers include Komatsu (KMTUY), Deere (DE) and AGCO (AGCO). Like Caterpillar, Joy Global (JOY) makes mining equipment. Fluor (FLR) and KBR (KBR) build major infrastructure projects. PRICE ACTION: In morning trading, Caterpillar sank 6.7% to $65.53, while Joy Global and Deere each dropped about 4%.
|10:11 EDT||JOY||Joy Global September weekly volatility increases on Caterpillar restructuring |
Joy Global (JOY) September weekly call option implied volatility is at 77, October is at 60, November is at 57; compared to its 52-week range of 26 to 70, suggesting large price movement after Caterpillar(CAT) announced restructuring plans to lower costs by $1.5B annually.
|September 23, 2015|
|10:48 EDT||MFC||Manulife Financial management to meet with UBS|
Subscribe for More Information
|September 22, 2015|
|20:02 EDT||CELG||Clinton vows $250 cap on monthly drug costs in blast against biotechs, insurers|
Democratic presidential candidate Hillary Clinton railed against biotech companies as well as health insurers at a community health care forum in Iowa on Tuesday. Clinton began her speech by praising the Affordable Care Act, but quickly noted that she wants to strengthen it due to what she called the rising cost of prescription drugs. She explained, "Our pharmaceutical and biotechnology industries deserve credit... [But] too often, these drugs cost a fortune. Now, sometimes there is a good reason for that. Scientific breakthroughs are often the result of major investment... so it may makes sense, for a short period of time, to have to charge a lot of money for a drug. But when a drug has no competition, when there aren't any other treatments that can do what it does, pharmaceutical companies can charge astronomical fees far beyond anything that it would take to recoup their investment, and far beyond what they charge consumers anywhere else in the world outside of America." Referencing the recent criticism against Turing Pharmaceuticals, Clinton went on to say that "pharmaceutical companies that acquire an existing affordable drug that people rely on, and then turn around and charge a fortune for it, [are just betting] on the fact that desperate people will find some way to pay for it." Preemptively responding to questions of whether greater regulation will dampen investment, Clinton commented that "some people worry that my proposals will threaten innovation, but I have designed a plan that will do exactly the opposite... Under my plan, drug companies that want to keep getting federal support will have to redirect more of their profits into meaningful investments in research and development." Clinton also criticized incremental drug improvements, saying that "too often, so-called new drugs are really old drugs that have just been tweaked a little bit, but then they're marketed as breakthrough drugs and they're sold for high prices." The Democratic candidate went on to condemn advertising in the drug industry, remarking that "I also want to tackle direct to consumer advertising... Other countries ban these ads because they are so often misleading. But at the very least, we shouldn't be encouraging them with corporate write-offs... Under my plan, we will instead use that taxpayer money to fund innovation... I would also like to make sure any ads the drug industry does run are approved by the FDA." Moving more broadly onto Medicaid and health insurers, Clinton stated, "I believe Medicare should be able to negotiate for lower prices for its members... I will require drug companies to provide higher rebates for prescription drugs to low income Medicare patients, just like they have to do for Medicaid patients... I think the insurance companies need to be put on notice." Providing more concrete details of her plan, Clinton concluded, "I will cap out of pocket drug costs for working families. You won't have to pay more than $250 a month for covered medications... Particularly for people who have a chronic illness. Also under my plan, you will be able to import cheaper drugs from other countries legally. If the medicine you need costs less in Canada, you should be able to buy it from Canada or any other country that meets our safety standards... I will also make sure we have more generics on the market [by boosting funding for] the FDA's office of generic drugs."
|17:56 EDT||KKR||KKR backs E&P team to launch Trans European Oil & Gas|
KKR announced earlier that it will back Roland Wessel, Colin Judd and Melvyn Horgan, founders and former management team of Star Energy, to launch Trans European Oil & Gas Limited. "Trans European Oil & Gas intends to build a portfolio of conventional onshore oil and gas properties in proven hydrocarbon plays in Europe, and apply its extensive experience in enhanced oil recovery techniques to optimize production," said KKR. The investment in Trans European Oil & Gas will be made primarily by the KKR European Fund IV.
|17:35 EDT||CELG||Hillary Clinton vows to cap out-of-pocket drug costs at $250 per month|
Presidential candidate Hillary Clinton said in a tweet that, "Under my plan, I'll cap out-of-pocket drug costs for families. You won't have to pay more than $250/month for covered medications." Reference Link
|17:28 EDT||FTI||FMC Technologies awarded contract for Shell Appomattox |
Subscribe for More Information
|13:05 EDT||PH||Parker-Hannifin sees 5-year CAGR EPS growth 8%|
Sees 8% EPS growth CAGR over a five-year period through FY20. Other targeted metrics by FY20 include: Organic sales growth 150 bps greater than Industrial growth; sales of $14B via organic growth; segment operating margins 17%; ROIC 17%; cash from operations greater than10%. Regarding capital deployment, though FY20, sees $1.8B in dividends, $1.2B in CapEx, $4B in strategic M&A and share buybacks. Comments from slides that will be presented at the company's investor meeting.
|08:23 EDT||CELG||Analysts say buy select biotech stocks ahead of Clinton drug plan|
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
|08:00 EDT||CELG||Jefferies sees buying opportunities in select biotech names|
Analysts at Jefferies say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). The Jefferies Biotechnology research team is led by Brian Abrahams, Eun Yang and Biren Amin.
|07:45 EDT||RDC||Global Hunter Securities to hold a bus tour|
Subscribe for More Information
|05:09 EDT||CELG||Stocks with implied volatility movement; BIIB CELG|
Stocks with implied volatility movement; Biogen (BIIB) 44m Celgene (CELG) 38 according to iVolatility.